Zhejiang Carbiogene Therapeutics Co., Ltd. (Carbiogene) is a “5050 Plan” company introduced by the Hangzhou National High-Tech Zone, and a National High-Tech Enterprise supported by government funding. Carbiogene is an innovative biotechnology company co-founded by renowned scientists from China and abroad, integrating R&D, production, and sales. Its core team is composed of internationally influential medical scientists.
Carbiogene's R&D and manufacturing center is built according to AABB standards, with a standard GMP clean workshop and world-class laboratory equipment. It has passed ISO certification for three management systems, establishing a closed-loop industry led by new anti-tumor immunotherapy products, including new-generation CAR-T and CAR-NK therapies, and supported by tumor DC vaccines, immune cells, stem-cell biological resources, molecular tumor diagnostics, laboratory testing, and medical health big data. Following the company philosophy, “cure sickness to save patients,” Carbiogene introduces the world's leading precision tumor immunotherapy technology platform and promotes the clinical translation of next-generation precision tumor immunotherapy, creating a globally influential and innovative biotechnology company.